MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing next-generation cell therapeutics - Net loss widens to USD37.9 million in 2023 from USD23.6.
IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.